Table 2. Correlations (r) between biomarker values at baseline for all patients and at week 24 for patients in the infliximab and placebo groups separately.

	VEGF	TGF-β	CTX	Osteocalcin	BAP
Baseline
IL-6	0.264***	0.105	0.112	0.064	0.040
VEGF		0.256***	0.052	0.014	0.084
TGF-β			0.034	0.089	0.148*
CTX				0.476***	0.367***
Osteocalcin					0.336***
Week 24: infliximab
IL-6	0.446***	0.123	0.035	−0.268**	−0.157*
VEGF		0.494***	0.021	−0.288**	−0.148****
TGF-β			0.074	0.051	0.095
CTX				0.273**	0.169*
Osteocalcin					0.391***
Week 24: placebo
IL-6	−0.019	−0.041	0.031	−0.130	−0.114
VEGF		0.564***	0.102	−0.058	0.087
TGF-β			0.162	−0.121	0.071
CTX				0.259*	−0.062
Osteocalcin					0.274*

BAP, bone alkaline phosphatase; CTX, C-terminal cross-linking telopeptide of type I collagen; IL-6, interleukin-6; TGF-β, transforming growth factor β; VEGF, vascular endothelial growth factor.

*p<0.05; **p<0.005; ***p<0.0001; ****p = 0.0513.